SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 57083.
  • 2
    Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 16916.
  • 3
    Garfein RS, Vlahou D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 65561.
  • 4
    Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123: 3307.
  • 5
    WHO. Hepatitis C. Accessed at http://www.who.int/mediacentre/factsheets/fs164/en/ on 21 February 2005.
  • 6
    Casiraghi MA, De Paschale M, Romano L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004; 39: 906.
  • 7
    Poynard T, Bedossa P, Opolon P. for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 82532.
  • 8
    Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. and the Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. Hepatology 1997; 26: 48590.
  • 9
    Benvegnu L, Alberti A. Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus-related cirrhosis. Antiviral Res 2001; 52: 199207.
  • 10
    Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 288695.
    Direct Link:
  • 11
    United Network for Organ Sharing. Organ Procurement and Transplant Network (OPTN) data as of March 1, 2002. Transplants by diagnosis: January 1991 to November 2001. Accessed at http://www.unos.org. on 10 January 2003.
  • 12
    WHO. Hepatitis C. Accessed at http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index5.html on 21 February 2005.
  • 13
    NIH Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997; 26(Suppl. 1): 2S10S.
  • 14
    Carithers Jr RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26(Suppl. 1): 83S8S.
  • 15
    Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht JK. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000; 32: 4004.
  • 16
    Myers RP, Regimbeau C, Thevenot T, et al. Interferon for interferon naive patients with chronic hepatitis C. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD000370. DOI: 10.1002/14651858.CD000370.
  • 17
    Gluud LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002234. DOI: 10.1002/14651858.CD002234.
  • 18
    Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD005445. DOI: 10.1002/14651858.CD005445.
  • 19
    Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol moiety optimizes the pharmacokinetics of peginterferon alpha-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC) [Abstract]. Hepatology 1999; 30 (Pt. 2):190A.
  • 20
    Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK; and the Hepatitis C Intervention Therapy Group. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68:55667.
  • 21
    Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 22
    Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 4338.
  • 23
    Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, and the Hepatitis C Intervention Therapy Group. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32: 64753.
  • 24
    Strader DB, Wright T, Thomas LD, Seeff LB. AASLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 114771.
  • 25
    Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C. The Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005441. DOI: 10.1002/14651858.CD005441.
  • 26
    HigginsJPT, GreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005].: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd.
  • 27
    Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Ann Intern Med 2001; 135: 9829.
  • 28
    Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 5377.
  • 29
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 30
    DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Stat Med 1987; 6: 34150.
  • 31
    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 62934.
  • 32
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 153958.
  • 33
    Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 6549.
  • 34
    Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36(Suppl. 1): S6573.
  • 35
    Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219.
  • 36
    Alfaleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 56874.
  • 37
    Bruno S, Camma C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 47481.
  • 38
    Esmat GH, Abouzied A, Abdel-Hamid M, et al. Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin [Abstract]. Hepatology 2003; 38(Suppl. 1): 314A5A.
  • 39
    Fargion S, Borzio M, Maraschi A, Cargnel A. Sustained virological response (SVR) to peginterferon alfa-2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs. induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponders (NR) with chronic hepatitis C (CHC) [Abstract]. J Hepatol 2004; 40(Suppl. 1): 140.
  • 40
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 41
    Hinrichsen H, Buggisch P, Nasser S, Foelsch UR. A prospective randomized 24 week trial of peg-interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [Abstract]. Hepatology 2002; 36 (Pt. 2): 311A.
  • 42
    Izumi N, Asahina Y, Kurosaki M, et al. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C. Intervirology 2004; 47: 1027.
  • 43
    Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepatitis 2005; 12: 28391.
  • 44
    Mangia A, Ricci GL, Persico M, et al. A randomized controlled trial of peginterferon alpha-2a (40 kD) or interferon alpha-2a plus ribavirin and amantadine vs. interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepatitis 2005; 12: 2929.
  • 45
    Mangia A, Cimino L, Persico M, et al. Enhanced response to peginterferon-alpha-2a-based triple therapy in previously non-responsive chronic hepatitis C: final results of PRETTY study [Abstract]. J Hepatol 2005; 42: 2001.
  • 46
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 95865.
  • 47
    Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. Microbiologica 2005; 28: 1321.
  • 48
    Nevens F, Van Vlierberghe H, D’heygere F, et al. Peginterferon alfa-2a (40 kDa) plus ribavirin is as effective in patients relapsing after conventional interferon based therapy as in naive patients: results from the BERNAR-1 trial [Abstract]. J Hepatol 2005; 42(Suppl.): 214.
  • 49
    Roffi L, Colloredo G, Del Poggio P, et al. Efficacy and safety of low doses of interferon (IFN) alfa-2b plus ribavirin (RBV) in advanced HCV related liver disease [Abstract]. Hepatology 2004; 40(Suppl. 1): 322A.
  • 50
    Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, Angarano G. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients. Microbiologica 2005; 28: 239.
  • 51
    Shobokshi A, Serebour FE, Skakni L, et al. Combination therapy of peginterferon alfa-2a (40kD) (Pegasys®) and ribavirin (Copegus®) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [Abstract]. Hepatology 2003; 38(Suppl. 1): 636A.
  • 52
    Sjögren MH, Sjögren Jr R, Lyons MF, et al. Antiviral response of HCV genotype-1 to consensus interferon and ribavirin compared with pegylated interferon and ribavirin: a preliminary report [Abstract]. Hepatology 2004; 1: 396A7A.
  • 53
    Tsubota A, Arase Y, Someya T, et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005; 75: 2734.
  • 54
    Zaman A, Fennerty MB, Keeffe EB. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2003; 18: 66170.
  • 55
    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8: 1125.
  • 56
    Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 10514.
  • 57
    Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36(Suppl. 1): S13544.
  • 58
    Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 130313.
  • 59
    Gluud LL. Bias in clinical intervention research. Am J Epidemiol 2006; 163: 493501.
  • 60
    Gluud C. The culture of designing hepato-biliary randomised trials. J Hepatol 2006; 44(3): 60715.